No link between Merck's Gardasil and MS risk, study shows

Merck's Gardasil HPV vaccine--FierceBiotech file photo
Merck's Gardasil

Merck ($MRK) and partner Sanofi ($SNY) can breathe easy: According to a new study, their blockbuster HPV shot Gardasil isn't linked to an increased risk of multiple sclerosis. In a study published Tuesday in JAMA, researchers found that in a population of 3.9 million girls and women, those vaccinated with Gardasil had lower rates of MS and similar CNS diseases. Story

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan